BiotechTube
Perrigo

Perrigo

PRGO
Dublin, Ireland· Est. 1887

Perrigo is a 138-year-old, publicly-traded company with a core mission to 'Make Lives Better Through Trusted Health and Wellness Solutions, Accessible to All.' It operates as a major player in the consumer self-care market, offering a broad portfolio of OTC products, infant formula, and generic pharmaceuticals, primarily through private-label and store-brand channels. The company leverages its extensive manufacturing and distribution capabilities to provide affordable alternatives to national brands, supported by a strong commitment to corporate responsibility through its charitable foundation. Its strategic direction focuses on expanding its self-care portfolio and driving growth in the global OTC market.

perrigo.com

PRGO · Stock Price

USD 9.6417.72 (-64.77%)
Market Cap: $1.3B

Historical price data

AI Company Overview

Perrigo is a 138-year-old, publicly-traded company with a core mission to 'Make Lives Better Through Trusted Health and Wellness Solutions, Accessible to All.' It operates as a major player in the consumer self-care market, offering a broad portfolio of OTC products, infant formula, and generic pharmaceuticals, primarily through private-label and store-brand channels. The company leverages its extensive manufacturing and distribution capabilities to provide affordable alternatives to national brands, supported by a strong commitment to corporate responsibility through its charitable foundation. Its strategic direction focuses on expanding its self-care portfolio and driving growth in the global OTC market.

Pain ManagementAllergyGastrointestinalSmoking CessationDermatologyCough/ColdInfant NutritionPersonal Care

Technology Platform

Integrated development, manufacturing, and regulatory platform for bioequivalent over-the-counter (OTC) consumer self-care products and generic pharmaceuticals, focused on private-label and store-brand supply.

Pipeline

7
7 drugs in pipeline
DrugIndicationStageWatch
Vivomixx + PlaceboBreast CancerPhase 1/2
Famotidine Tablets, 40 mgBioavailabilityPhase 1
Naproxen Tablets, 500 mgBioequivalencyPhase 1
Ibuprofen Tablets, 800 mgBioequivalencyPhase 1
Naproxen Tablets, 500 mgBioequivalencyPhase 1

Funding History

2
Total raised:$800M
Debt$800MJul 15, 2013
IPOUndisclosedJun 15, 1991

FDA Approved Drugs

49
NASONEX 24HR ALLERGYNDAMar 17, 2022
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDEANDAFeb 1, 2022
FEXOFENADINE HYDROCHLORIDEANDAFeb 24, 2020

Opportunities

Perrigo's growth opportunities include capitalizing on the strong trend toward private-label products among retailers, expanding into new geographic markets, developing products for Rx-to-OTC switch candidates, and broadening its portfolio into adjacent self-care categories like vitamins and supplements.
Digital consumer engagement also presents a channel for building brand trust and guiding product development.

Risk Factors

Key risks include high customer concentration with a few major retailers, intense price competition in the OTC and generic markets, regulatory and compliance challenges across global operations, vulnerability to supply chain disruptions and input cost inflation, and potential patent litigation when launching generic equivalents.

Competitive Landscape

Perrigo competes directly with national brand manufacturers (e.g., J&J, Bayer, GSK) through its store-brand equivalents, and with other private-label suppliers and generic pharma companies. Its differentiation lies in its massive scale, deep retailer partnerships, efficient supply chain, and ability to offer a wide range of affordable, high-quality OTC and generic products as a one-stop-shop for retailers.